We are live on ! Find out more
PDLI

PDL BioPharma, Inc.
PDLI

Delisted

PDLI was delisted on the 30th of December, 2020.

Back to rankings

212 hedge funds and large institutions have $1.08B invested in PDL BioPharma, Inc. in 2013 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 82 increasing their positions, 63 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

377% more call options, than puts

Call options by funds: $12.2M | Put options by funds: $2.56M

80% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 15

30% more repeat investments, than reductions

Existing positions increased: 82 | Existing positions reduced: 63

5% more funds holding

Funds holding: 202 → 212 (+10)

4% more capital invested

Capital invested by funds: $1.04B → $1.08B (+$39.2M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
212
Holders Change
+10
Holders Change %
+4.95%
% of All Funds
6.85%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
27
Increased
82
Reduced
63
Closed
15
Calls
$12.2M
Puts
$2.56M
Net Calls
+$9.65M
Net Calls Change
+$7.83M

Top Buyers

Rank Fund Capital Flow
1
GC
Guggenheim Capital
Illinois
+$8.57M
2
AAM
Advisors Asset Management
Colorado
+$6.55M
3
Schroder Investment Management Group
Schroder Investment Management Group
United Kingdom
+$6.47M
4
BFA
BlackRock Fund Advisors
California
+$5.81M
5
Bank of New York Mellon
Bank of New York Mellon
New York
+$4.73M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$41.1M
2
AQR Capital Management
AQR Capital Management
Connecticut
-$18.5M
3
HSA
Hussman Strategic Advisors
Maryland
-$4.75M
4
TC
TFS Capital
Pennsylvania
-$4.51M
5
Capital Fund Management (CFM)
Capital Fund Management (CFM)
France
-$3.21M

PDLI Hedge Fund Activity: Q3 2013 in Review

212 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q3 2013, worth a combined $1.08B — up 3.8% from $1.04B a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new PDLI positions and 15 closed out — a net gain of 12 holders — while 82 added to existing stakes and 63 trimmed.

The largest buyer was Guggenheim Capital, adding an estimated $8.57M. The largest seller was Fidelity Investments, cutting an estimated $41.1M.

  • 212 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q3 2013, up from 202 in Q2 2013.
  • Funds reported $1.08B of PDL BioPharma, Inc. stock for Q3 2013, up 3.8% quarter-over-quarter.
  • 27 funds opened new PDL BioPharma, Inc. positions in Q3 2013 and 15 closed out, a net change of +12 holders.
  • The largest PDL BioPharma, Inc. buyer in Q3 2013 was Guggenheim Capital, an estimated $8.57M added.
  • The largest PDL BioPharma, Inc. seller in Q3 2013 was Fidelity Investments, an estimated $41.1M sold.

Based on aggregated 13F filings for Q3 2013.